1. Home
  2. GROV vs EDSA Comparison

GROV vs EDSA Comparison

Compare GROV & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.04

Market Cap

52.1M

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$4.11

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
EDSA
Founded
2016
2015
Country
United States
Canada
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.1M
51.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
GROV
EDSA
Price
$1.04
$4.11
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$1.60
$5.00
AVG Volume (30 Days)
98.4K
55.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
N/A
EPS
N/A
N/A
Revenue
$173,716,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.72
52 Week High
$1.57
$20.32

Technical Indicators

Market Signals
Indicator
GROV
EDSA
Relative Strength Index (RSI) 50.25 35.63
Support Level $0.86 $1.34
Resistance Level $1.15 $5.10
Average True Range (ATR) 0.07 0.30
MACD 0.00 -0.01
Stochastic Oscillator 53.04 21.46

Price Performance

Historical Comparison
GROV
EDSA

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: